Loss of Raf-1-binding activity of v-Ha-Ras by the deletion of amino acid residues 64-72 and 143-151.
暂无分享,去创建一个
S. Sakiyama | T. Hiwasa | S Sakiyama | T Hiwasa | M Kasama | T Nakadai | T Sawada | T. Sawada | T. Nakadai | M. Kasama
[1] M. Weber,et al. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. , 1993, Science.
[2] D. Lowy,et al. Mutational analysis of a ras catalytic domain , 1986, Molecular and cellular biology.
[3] W. Kolch,et al. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells , 1991, Nature.
[4] S. Sakiyama,et al. Cysteine proteinase inhibitors and ras gene products share the same biological activities including transforming activity toward NIH3T3 mouse fibroblasts and the differentiation-inducing activity toward PC12 rat pheochromocytoma cells. , 1990, Carcinogenesis.
[5] S. Yokoyama,et al. Degradation of a cAMP-binding protein is inhibited by human c-Ha-ras gene products. , 1987, Biochemical and biophysical research communications.
[6] S H Kim,et al. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. , 1992, Science.
[7] S. Demo,et al. ralGDS family members interact with the effector loop of ras p21 , 1994, Molecular and cellular biology.
[8] W. Xie,et al. The cysteine-rich region of raf-1 kinase contains zinc, translocates to liposomes, and is adjacent to a segment that binds GTP-ras. , 1994, The Journal of biological chemistry.
[9] L. Sanz,et al. Evidence for the in vitro and in vivo interaction of Ras with protein kinase C zeta. , 1994, The Journal of biological chemistry.
[10] S. Sakiyama,et al. v‐Ha‐Ras insertion/deletion mutants with reduced protease‐inhibitory activity have no transforming activity , 1993, FEBS letters.
[11] A. Wolfman,et al. Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets. , 1995, Oncogene.
[12] S. Elledge,et al. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1 , 1993, Nature.
[13] D. Lowy,et al. Transforming p21 ras protein: flexibility in the major variable region linking the catalytic and membrane‐anchoring domains. , 1985, The EMBO journal.
[14] G. Landreth,et al. The mitogen-activated protein kinase cascade is activated by B-Raf in response to nerve growth factor through interaction with p21ras , 1994, Molecular and cellular biology.
[15] S. Sakiyama,et al. c‐Ha‐ras gene products are potent inhibitors of cathepsins B and L , 1987, FEBS letters.
[16] F. McCormick,et al. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. , 1987, Science.
[17] C. Der,et al. Two Distinct Raf Domains Mediate Interaction with Ras (*) , 1995, The Journal of Biological Chemistry.
[18] H. Maruta,et al. The minimal fragments of c-Raf-1 and NF1 that can suppress v-Ha-Ras-induced malignant phenotype. , 1994, The Journal of biological chemistry.
[19] M. Shirouzu,et al. Mutations that abolish the ability of Ha-Ras to associate with Raf-1. , 1994, Oncogene.
[20] X. F. Zhang,et al. Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues , 1994, Molecular and cellular biology.
[21] R. Jove,et al. Raf-1 N-terminal sequences necessary for Ras-Raf interaction and signal transduction , 1995, Molecular and cellular biology.
[22] P. Warne,et al. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro , 1993, Nature.
[23] T. Bonner,et al. Structure and biological activity of human homologs of the raf/mil oncogene , 1985, Molecular and cellular biology.
[24] Michael J. Fry,et al. Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.